RSC Advances

PAPER

Check for updates

Cite this: RSC Adv., 2017, 7, 32216

Received 11th May 2017 Accepted 12th June 2017

DOI: 10.1039/c7ra05348g

rsc.li/rsc-advances

Introduction

MicroRNAs (miRNAs) are small endogenous non-coding RNAs of about 22 nt long. MiRNAs are involved in many important biological processes, including cell development, proliferation, differentiation, apoptosis, and cellular signalling.¹⁻⁶ Increasing evidence has indicated that miRNAs play important roles in the development and progression of human diseases.⁷⁻⁹ Aberrant miRNA expression has been associated with many types of human disease, including cancers, such as cardiovascular diseases,¹⁰ prostate neoplasms,¹¹ and breast neoplasms.¹² Therefore, prediction and identification of disease-related miRNAs are critical to understand the pathogenesis of diseases, and thereby improve disease prognosis, diagnosis, treatment, and prevention.

In the last few years, many efforts have been exerted to identify potential miRNA-disease associations. Research using biological experimentation has determined a large number of miRNA-disease associations. Databases such as HMDD,¹³ miR2Disease,¹⁴ dbDEMC,¹⁵ miRCancer¹⁶ have been built to provide a platform for searching experimentally verified miRNA-disease associations. HMDD and miR2Disease are

A network similarity integration method for predicting microRNA-disease associations[†]

Xiaoying Li, D Yaping Lin* and Changlong Gu

Increasing evidence has indicated that microRNAs (miRNAs) regulate gene expression at the posttranscriptional level. Aberrant miRNA expression has been associated with many types of human disease, including cancers. Their associations can be used to understand the pathogenesis of diseases. However, using experimental methods to identify the associations between diseases and miRNAs is time consuming and costly. Computational methods could find the most promising miRNA-disease associations in a short time, thereby significantly reducing experimental time and cost. This paper presents a network similarity integration method (NSIM) for predicting potential miRNA-disease associations, considering that diseases associated with highly related miRNAs are more similar (and vice versa). The NSIM is based on 5425 experimentally verified human miRNA-disease associations, which consist of 495 miRNAs and 381 diseases. The NSIM integrates the disease similarity network, miRNA similarity network, and known miRNA-disease association network on the basis of cousin similarity to predict novel miRNA-disease associations. We evaluate the NSIM using leave-one-out cross validation. The area under the curve of the method is 0.9475, indicating its outstanding performance. Case studies on prostate, breast, and colon neoplasms further proved the outstanding performance of the NSIM to predict not only disease-related miRNAs but also isolated diseases (diseases without any related miRNAs).

> a collection of experimentally supported human miRNA-disease associations, manually retrieved on the basis of the literature. Database miRCancer stores miRNA-cancer associations, which are extracted using the rule-based text mining method. In addition, dbDEMC stores differentially expressed miRNAs in 14 human cancers by using significance analysis of microarrays to retrieve the miRNAs that have different expression levels in cancers when compared with normal tissues. These databases serve as a solid data foundation for predictive research of miRNAs in human diseases.

> Considering that the experimental identification of diseaserelated miRNAs is time consuming and expensive, researchers proposed computational methods as important complementary ways to predict miRNA-disease associations. Computational methods mainly aim to select the most promising diseaserelated miRNAs for further experimental examination to reduce experimental time and cost. The key problem in miRNAdisease association inference is similarity calculation. These computational methods are divided into two categories:¹⁷ network-based methods¹⁸⁻²⁶ and machine-learning-based methods.²⁶⁻³⁰

> Network-based methods predict miRNA-disease associations in consideration of the hypothesis that functionally related miRNAs are usually associated with phenotypically similar diseases.¹³ This hypothesis was proposed by Lu *et al.*¹³ when they analyzed the human miRNA-disease association data in HMDD. Basing on this hypothesis, Jiang *et al.*¹⁸ constructed





View Article Online

View Journal | View Issue

College of Information Science and Engineer, Hunan University, Changsha, Hunan 410012, China

[†] Electronic supplementary information (ESI) available: A supplemental table is available as a single excel file. See DOI: 10.1039/c7ra05348g

Paper

a functional association miRNA network, i.e., a human phenome-miRNAome network. For a given disease, they computed the similarity score of all human miRNAs in these networks and then prioritized all these miRNAs according to score. The top-ranked miRNAs were expected as the potential disease miRNAs. However, this model uses only the neighboring information of each miRNA and strongly relies on predicted miRNA-target interactions, thereby producing falsepositive and false-negative results, that can influence the final prediction accuracy. Shi et al.21 presented a computational framework to identify miRNA-disease associations and further constructed a bipartite miRNA-disease network for systematically analyzing the global properties of miRNA regulation of disease genes. From these analyses, they found that most diseases in the same co-regulated module belong to the same category. Their work extended the previous hypothesis. However, this method is limited in application because of the low accuracy of target prediction and the fact that many disease-gene associations of miRNA-target interactions are unknown. On the basis of the weighted k most similar neighbours, HDMP²² was proposed to predict disease-related miR-NAs. HDMP was used to evaluate the function similarity between miRNAs by considering disease terms and the phenotype similarity between diseases, as well as assigning higher weight to members of the miRNA family or cluster. However, HDMP only considers local network similarity measure and disregards diseases without any known related miRNA. Recently, Zou et al.26 have presented method KATZ, which uses the functional similarity score to denote the associations on the basis of the different lengths between the miRNA and disease nodes. However, the performance of KATZ is relatively poor on the spare known associations.

Machine-learning-based methods have been used to solve the problem by improving the classification accuracy and prediction performance. Jiang et al.29 proposed a Naïve Bayes model to rank candidate disease-related miRNAs through genomic data integration. This method strongly relies on datasets of disease-gene associations and miRNA-target interactions, but over half of human diseases are still unknown. To distinguish positive miRNA-disease associations from negative ones, Jiang et al.27 proposed a support vector machine approach by extracting the features based on miRNA-target data and phenotype similarity data. Considering the assumption that miRNAs implicated in a specific tumor phenotype show aberrant regulation of their target genes, Xu et al.30 prioritized novel disease miRNAs on the basis of the miRNA target-dysregulated network method. The common problem of the two aforementioned methods is that the negative training samples consisting of non-association between miRNAs and diseases do not demonstrate sufficient statistical confidence; the lack of a miRNA-disease association during observation in a biological experiment does not directly indicate absence of such an association. Chen et al.28 developed regularized least squares for miRNA-disease association (RLSMDA) to find potential miRNA candidates for a specific disease. RLSMDA is a semi-supervised method that integrates known disease-miRNA associations, disease-disease similarity dataset, and miRNA-miRNA

functional similarity network. Despite its good prediction performance for diseases with or without related miRNAs, RLSMDA does not consider the topology information of the miRNA network.

The aforementioned methods have three main limitations. First, some methods are inefficient at cross-validation. Second, some approaches are unable to predict isolated disease-related miRNAs. Third, negative samples are difficult to obtain for some machine learning methods. Consequently, we propose a network similarity integration method (NSIM) to solve these limitations. The NSIM integrates miRNA similarities, diseases similarities, and known miRNA-disease association information to predict potential miRNA-disease associations. The advantages of the NSIM are as follows. First, this method is easy to understand and can effectively be implemented. Cross validations and global predictions for all 381 diseases are run simultaneously. Second, case studies about prostate, breast, and colon neoplasms demonstrate that the NSIM has good predictive performance. Third, the NSIM can also predict isolated diseases.

Materials

Dataset

The database we used in this study contains data on miRNAmiRNA functional similarities, disease semantic similarities, and known human miRNA-disease associations. Below is a brief description of these data.

Known human miRNA-disease associations

Data on known human miRNA-disease were downloaded from HMDD 2.0 (ref. 13) (http://www.cuilab.cn/hmdd, Jun-14-2014 Version). We removed duplicated associations and those associations whose disease could not be mapped to the MeSH database or whose disease did not have a related MeSH tree number. After filtering, we finally received 5425 high-quality experimentally verified human miRNA-disease associations consisting of 495 miRNAs and 381 diseases in the dataset. Matrix AS denotes miRNA-disease associations and AS(i_i) = 1 means there exists a validated association between miRNA *i* and disease *j*; otherwise, AS(i_i) = 0.

Disease directed acyclic graph

In our study, a functional similarity score for each disease pair was calculated based on the hypothesis that miRNAs with similar functions used to be associated with similar diseases. We improved the detailed description provided by ref. 19 about the calculated method. The diseases are mapped to the MeSH database (the website is http://www.ncbi.nlm.nih.gov/), and their MeSH headings (or called descriptors) are downloaded. Each MeSH heading shows a tree structure of a hierarchical organization. This tree structure of a disease is described as a directed acyclic graph (DAG). The nodes of the tree represent diseases while the edges represent the relationship between the parent node and their children nodes. The higher the hierarchy of a node is, the more general its meaning is. Otherwise, the



lower the hierarchy is, the more specific its meaning is. The DAG of gastrointestinal neoplasms is shown in Fig. 1.

Methods

Based on the information of experimentally validated miRNAdisease association network and two common assumptions, we reconstructed miRNA and disease similarity networks, and employed the NSIM to predict potential miRNA-disease associations. One of the assumptions is miRNAs with similar functions are normally associated with phenotypically similar diseases and vice versa,^{13,31} and the other is diseases with similar functions are often having similar semantic descriptions and vice versa.¹⁹ The NSIM contains four processes. First, it calculates the semantic similarity score of diseases according to the semantic tree structure. Second, it calculates miRNA-miRNA functional similarities based on the semantic similarity score of diseases. A miRNA functional network was built on the basis of these calculations. Third, it calculates the similarity score of diseases to reconstruct a disease similarity network by considering the disease semantic similarities and disease similarities of known miRNA-disease associations. Fourth, it integrates the disease similarities, miRNA similarities, and known miRNA-disease associations to predict potential associations between miRNAs and diseases. The flowchart of the NSIM is shown in Fig. 2.

Measurement of disease semantic similarities

Some researchers have measured the similarity of diseases by the hierarchical structure of disease semantics.^{19,32} In this work, the semantic similarity measure for disease is developed based on Wang *et al.*,¹⁹ but not the same as it.

A disease A can be represented as a graph, $DAG(A) = (A, T_A, E_A)$, where T_A is the set of all ancestor nodes of A including A itself and E_A is the set of corresponding links of A. The contribution of ancestor node *t* to A is defined as follows:

$$\begin{cases} D_{A}(A) = 1\\ D_{A}(t) = \max\left\{\Delta \times D_{A}(t') \middle| t' \in \text{children of } t\right\} & \text{if } t \neq A. \end{cases}$$
⁽¹⁾

where Δ is the semantic contribution factor for edges E_A linking disease *t* with its child disease *t'*. The semantic value of disease A is defined as follows:

$$DV(A) = \sum_{t \in T_A} D_A(t).$$
 (2)



Fig. 2 The flowchart of NSIM.

The semantic similarity score of disease A and disease B is defined as:

$$DD(A,B) = \frac{\sum_{t \in T_A \cap T_B} D_A(t) + \sum_{t \in T_A \cap T_B} D_B(t)}{2 \times \min(DV(A), DV(B))}.$$
 (3)

where *t* is the disease terms both in T_A and T_B . $D_A(t)$ is the semantic value of disease *t* related to disease A and $D_B(t)$ is the semantic value of disease *t* related to disease B. The semantics similarity score between disease A and disease B not only depends on the number of common diseases of A and B but also on these common diseases' total semantic relations value. The more the total number of common diseases is and the higher the total semantic value of common diseases is, the higher the score is.

Measurement of miRNA functional similarity

We define $DS_j = \{d_1, d_2, \dots, d_n\}$, the disease set associated with miRNA *j*. The related score between disease $d \in DS_i$ and set DS_j is defined as follows:

$$DM(d, DS_j) = \max_{1 \le t \le n} (DD(d, DS_j(t))).$$
(4)

Here, we define the maximum similarity of disease d and diseases in DS_j as the related score between disease d and miRNA *j*.

We define matrix MM as the miRNA-miRNA function similarity matrix, where MM(i,j) in row *i* and column *j* expresses the functional similarity score between miRNA *i* and miRNA *j*. By considering the contribution of the similarity diseases, the functional similarity of MM(i,j) is calculated as follows:

$$\mathrm{SMD}_i = \sum_{\mathrm{d}\in \mathrm{DS}_i} \mathrm{DM}(\mathrm{d},\mathrm{DS}_j)$$

$$\mathbf{MM}(i,j) = \frac{\mathbf{SMD}_i + \mathbf{SMD}_j}{|\mathbf{DS}_i| + |\mathbf{DS}_j|}.$$
(5)

Paper

where SMD_{*i*} is the similarity score of miRNA *i* and disease set DS_{*j*}, and SMD_{*j*} is the similarity score of miRNA *j* and disease set DS_{*i*}. $|DS_i|$ is the number of the known diseases associated with miRNA *i*, and $|DS_j|$ is the number of the known diseases associated with miRNA *j*.

Reconstruction of a disease similarity network

A disease similarity network was reconstructed by considering the disease semantic similarities and disease similarities of known miRNA-disease associations. Considering the assumption that the more common miRNAs of a disease pair has, the more similar they are, we define the disease similarity value of a known disease-miRNA association on the basis of matrix AS and Jaccard similarity measurement as

$$DAS(i,j) = \frac{M_{11}}{M_{01} + M_{10} + M_{11}}.$$
 (6)

Considering disease *i* and disease *j* in matrix AS, we count the total number of commonly associated miRNAs of disease *i* and *j*, and then define it as M_{11} . Similarly, M_{01} represents the total number of miRNAs that are only associated with disease *i*, M_{10} represents the total number of miRNAs that are only associated with disease *j*. The total number of miRNAs that are not associated with neither *i* nor *j* is disregarded. For a certain disease pair, the similarity value is set to 0 when the total number of miRNAs associated with these two diseases is zero.

We reconstruct the disease similarity network as:

$$SD(i,j) = \frac{DD(i,j) + DAS(i,j)}{2}.$$
(7)

where SD(i,j) is the final disease similarity value of disease *i* and disease *j*. In this formula, the more similar disease *i* and disease *j* in the known association network are and the higher the disease semantic similarity between them, the higher their similarity value is. We hypothesize that the disease semantic similarity is as important as the disease similarity calculated by the known association network. Thus, the same weight is given to form the disease similarity measurement.

NSIM for miRNA-disease associations

The NSIM calculates the potential miRNA-disease association scores by integrating the miRNA and disease vector space score. Cosine similarity is employed to calculate the vector space score.

In the miRNA vector space, the similarity between miRNA i and all miRNAs is described as a vector VMM_i, and MM_i, (the *i*th row of matrix MM) is used to represent it. Likewise, the similarity between the associations of disease j and all miRNAs is described as a vector VD_j, and AS_j (the *j*th column of matrix AS) is used to represent it.

$$VMM_i = MM_i,$$

 $VD_i = AS_i$

The miRNA space score is defined as

$$NSIM_M(i,j) = \frac{VMM_i \cdot VD_j}{\|VMM_i\| \|VD_j\|}.$$
(8)

where $VMM_i \cdot VD_j$ is the dot product of vector VMM_i and VD_j ; || VMM_i || is the norm of vector VMM_i , || VD_j || is the norm of vector VD_j . NSIM_M(i,j) is the cosine similarity of vector VMM_i and VD_j . Obviously, the smaller angle between VMM_i and VD_j is, the greater the vector space score NSIM_M(i,j) is.

Obviously, the higher the spatial similarity of miRNA *i*-associated miRNAs in the miRNA-miRNA similarity network is, the greater the association between miRNA *i* and disease *j* is. Similarly, the higher the spatial similarity of disease *j*-associated miRNAs in the known miRNA-disease network is, the greater the association between miRNA *i* and disease *j* is.

In the disease vector space, the similarity between the associations of miRNA *i* and all diseases is described as a vector VM_{*i*}. We could use AS_{*i*}, (the *i*th row of matrix AS) to represent it. Similarly, the similarity between disease *j* and all diseases is described as vector VSD_{*j*}, and we could use SD_{*j*} (the *j*th column of matrix SD) to represent it.

$$VM_i = AS_i,$$

 $VSD_j = SD_j$

The disease space score is defined as

$$\mathrm{NSIM}_{\mathrm{D}}(i,j) = \frac{\mathrm{VM}_i \cdot \mathrm{VSD}_j}{\|\mathrm{VM}_i\| \|\mathrm{VSD}_j\|}.$$
(9)

where $VM_i \cdot VSD_j$ is the dot product of vector VM_i and VSD_j ; $||VM_i||$ is the norm of vector VM_i , $||VSD_j||$ is the norm of vector VSD_j . $NSIM_D(i,j)$ is the cosine similarity of vector VM_i and VSD_j . Notably, the smaller angle between VM_i and VSD_j is, the greater the vector space score $NSIM_D(i,j)$ is.

Obviously, that the higher the spatial similarity of miRNA iassociated diseases in the known miRNA-disease network is, the greater the association of miRNA i and disease j is. Likewise, the higher the spatial similarity of the disease j associated diseases in disease similarity network is, the greater the association of miRNA i and disease j is.



Fig. 3 Average AUCs affected by α value.

Finally, the miRNA space score and disease space score are integrated together as

$$NSIM(i,j) = \alpha \times NSIM_M(i,j) + (1 - \alpha) \times NSIM_D(i,j)$$
(10)

where α is a parameter to balance the contributions from the two space similarities, $\alpha \in (0,1)$. NSIM(i,j) in row *i* column *j* is the prediction-related score of miRNA *i* to disease *j*. To find a suitable α value, the different α values from 0.1 to 1 were investigated by the experiments. Fig. 3 shows that the NSIM achieves the highest prediction performance when α is 0.5.

Results

Performance evaluation of the NSIM

In our study, we implemented leave-one-out cross validation (LOOCV) on experimentally verified miRNA-disease associations to evaluate the predictive performance of the NSIM. Each known miRNA-disease association was left out in turn as a test sample, and other known miRNA-disease associations were taken as a training set. A receiver operating characteristic (ROC) curve was plotted by varying the threshold, and the value of area under curve (AUC) was calculated. In the ROC, the vertical and horizontal axes are the true positive rate (TPR, sensitivity) and false positive rate (FPR, 1-specificity) at different thresholds, respectively. Sensitivity refers to the percentage of test miRNAs with ranking above a given threshold, whereas specificity refers to the percentage of associations below the threshold. When the AUC is closer to 1, the prediction performance is better.

To our knowledge, HDMP,²² RLSMDA,²⁸ KATZ,²⁶ and the global network algorithm developed by Shi *et al.*²¹ are the-stateof-art computational approaches to predict miRNA-disease associations. We compared NSIM with RLSMDA and KATZ. HDMP could not predict disease without known associated miRNAs; the method developed by Shi *et al.* integrated the dataset from disease gene associations, miRNA-target



Fig. 4 The comparison result between NSIM, RLSMDA and KATZ was shown, which demonstrated the superiority performance of NSIM to other two methods.

interactions, and protein interactions, which were different from the dataset used in the NSIM.

We implemented a LOOCV for RLSMDA and KATZ. In the present study, the NSIM achieved an AUC value of 0.9475 when α is 0.5. For RLSMDA, when optimal parameters were selected as described in the literature, the AUC value was 0.8870. For KATZ, the AUC value was 0.9202. The comparison result of overall AUC between NSIM and RLSMDA, KATZ is shown in Fig. 4.

To obtain reliable judgment, we tested 19 human diseases that are related to at least 70 microRNAs respectively. As shown in Table 1, the NSIM achieved the highest AUC of 0.9446 with lung neoplasms and the lowest AUC of 0.8813 with esophageal neoplasms. The average AUC value for the 19 diseases was 0.9125 (Table 1). For RLSMDA, the average AUC value for the 19 diseases was 0.8450. The average AUC value was increased by 6.75%. For KATZ, the average AUC value for the 19 diseases was 0.8945. The average AUC value of the NSIM was 1.8% higher than that of KATZ. The AUC values of the NSIM for of neoplasms and ovarian neoplasms were lower than those of RLSMDA and KATZ. The AUC values of the NSIM for the 17 other diseases were all higher than those of RLSMDA and KATZ. Obviously, the prediction performance of NSIM was more accurate than those of RLSMDA and KATA.

Comprehensive prediction of unknown associations

The NSIM was utilized to predict unknown microRNA-disease associations. Initially, the related score of each microRNAdisease pair was calculated by using all known and experimented microRNA-disease associations. Then, the unknown associations were ranked by their scores. Finally, the top 50 associations were manually verified through two databases: dbDEMC (the database is being upgraded, the experimental verified microRNA-disease associations are obtained from the author) and miRCancer. The predicted results are listed in Table S1 (ESI†), and their verified evidences is presented. For the top 50 predictive associations, all 50 had been confirmed in the aforementioned databases.

Case studies

Many researchers have found more and more evidences that microRNAs are related with various human cancers.^{8,3343536} To further evaluate the performance of the NSIM to predict disease-associated miRNA candidates, we selected prostate, breast, and colon neoplasms as case studies.

Prostate neoplasm is the most common cancer among males in 84 countries,³⁵ especially in developed countries. Prostate neoplasm is the second most common type of cancer and the fifth leading cause of cancer-related death among men worldwide.³⁷ MiRNAs are over expressed during the progression of prostate neoplasms. Thus, miRNAs are promising diagnostic or prognostic biomarkers. For example, miR-409-3p, miR-361-3p, miR-133b, miR-221, and miR-128 are under expressed and miR-375, miR-141, miR-378*, and miR-203 are upregulated in prostate cancer.³⁸⁻⁴⁰ Candidate miRNAs were ranked in terms of scores obtained from the NSIM. The top 20 potential miRNAs

Table 1 Prediction results of NSIM and other methods for LOOCV

	Number of associated microRNAs	AUC		
Disease name		NSIM	RLSMDA	KATZ
Breast neoplasms	202	0.9353	0.8951	0.9296
Carcinoma, hepatocellular	214	0.9119	0.8631	0.9012
Carcinoma, non-small-cell lung	95	0.9031	0.8342	0.8800
Carcinoma, renal cell	107	0.8926	0.8172	0.875
Carcinoma, squamous cell	80	0.9048	0.8386	0.8895
Colonic neoplasms	78	0.8834	0.8232	0.8728
Colorectal neoplasms	147	0.8845	0.8461	0.8819
Esophageal neoplasms	74	0.8813	0.7747	0.8466
Glioblastoma	96	0.9006	0.7934	0.8595
Glioma	71	0.9131	0.8704	0.9114
Heart failure	120	0.9071	0.8454	0.8636
Lung neoplasms	132	0.9446	0.7844	0.9249
Melanoma	141	0.9185	0.8850	0.8903
Neoplasms	110	0.9436	0.8339	0.9751
Ovarian neoplasms	114	0.9286	0.9630	0.9271
Pancreatic neoplasms	99	0.9312	0.8991	0.9126
Prostatic neoplasms	118	0.9209	0.8665	0.883
Stomach neoplasms	174	0.9104	0.8217	0.8984
Urinary bladder neoplasms	92	0.9227	0.8493	0.8732

associated with prostate neoplasms and evidence for the associations with prostate are listed in Table 2. Among the top 20 predicted prostate-related miRNAs, 18 have been confirmed by dbDEMC or miRCancer. Unconfirmed potential miRNA with the highest rank is has-mir-17 (ranked 4th). However, we found in the literature^{41,42} that the miR-17 family is over expressed in prostate neoplasms by targeting the p300/CBP-associated factor and modulating androgen receptor transcriptional activity in cultured prostate neoplasms cells.

Table 2 The top 20 potential prostate neoplasms-related miRNAs predicted by NSIM and the confirmation of these associations. Eighteen of the top 20 prostate neoplasms-related miRNAs have been confirmed based on the miRCancer and dbDEMC databases

Rank	miRNA	Evdances
1	Hsa-mir-182	dbDEMC, miRCancer
2	Hsa-mir-143	dbDEMC, miRCancer
3	Hsa-mir-21	dbDEMC, miRCancer
4	Hsa-mir-17	PMID: 27650539
5	Hsa-mir-34a	dbDEMC, C
6	Hsa-mir-100	dbDEMC, miRCancer
7	Hsa-mir-126	dbDEMC
8	Hsa-mir-150	dbDEMC
9	Hsa-mir-20a	miRCancer
10	Hsa-mir-142	Unconfirmed
11	Hsa-mir-200a	dbDEMC
12	Hsa-mir-203	miRCancer
13	Hsa-mir-141	miRCancer
14	Hsa-mir-31	dbDEMC, miRCancer
15	Hsa-mir-146a	miRCancer
16	Hsa-mir-96	dbDEMC, miRCancer
17	Hsa-mir-200c	dbDEMC
18	Hsa-mir-200b	miRCancer
19	Hsa-mir-223	dbDEMC, miRCancer
20	Hsa-mir-9	dbDEMC

Breast neoplasm is the most common invasive cancer among women especially in developed countries, accounting for 25% of cancer cases among women. MiRNAs play regulatory roles in the invasion and metastasis of breast neoplasms. For example, miR-182, miR-21 are over expressed in breast neoplasms,12,35 and miR-205, miR-200c, miR-141, and miR-429 are down regulated in breast cancer.43 The top 20 potential miRNAs associated with breast neoplasms and evidence for the associations with breast are listed in Table 3. Among these candidate miRNAs, only 4 were not confirmed in the dbDEMC or miR-Cancer dataset. However, the literature⁴⁴ provided information that miRNA hsa-mir-542 induces angiogenic inhibition in breast neoplasms.

Colon neoplasm is the third most common cancer in the digestive tract worldwide. MiRNAs can be accurately diagnosed as biomarkers of colon neoplasms and can help predict colon neoplasms.45,46 MiRNA differential expression provides a promising application for early diagnosis and screening of colon neoplasms. For example, miR-21, miR-155, miR-31, miR-92a, and miR-17 are involved in the development of colon neoplasms.47 The top 20 potential miRNAs associated with colon neoplasms and evidence for the associations with colon neoplasms are listed in Table 4. Among these candidate miR-NAs, 5 were not confirmed by the dbDEMC or miRCancer dataset. Nevertheless, they all have been identified in the literature. The PMID of the literature is shown in the tables.

The above results demonstrate that the NSIM performs well in predicting potential disease-associated miRNA candidates.

Application of NSIM to predict isolated diseases

An isolated disease refers to a disease without any known related miRNAs. To demonstrate the predictive ability of NSIM on diseases without any known related miRNA, we removed the Rar

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

Table 3The top 20 potential breast neoplasms-related miRNAspredicted by NSIM and the confirmation of these associations. Sixteenof the top 20 breast neoplasms-related miRNAs have been confirmedbased on the mirCancer and dbDEMC databases

niRNAs Sixteen nfirmed	Table 5The top 20 potential isolated disease predicted of breastneoplasms. Fourteen of the top 20 breast neoplasms-related miRNAshave been confirmed based on the mirCancer and dbDEMC databases			
	Rank	miRNA name	Evidences	
	1	Hea-mir-99a	dbDFMC_miRCancer	

ık	miRNA	Evidences
	Hsa-mir-99a	dbDEMC, miRCancer
	Hsa-mir-138	dbDEMC
	Hsa-mir-142	miRCancer
	Hsa-mir-106a	dbDEMC
	Hsa-mir-130a	dbDEMC, miRCancer
	Hsa-mir-378a	Unconfirmed
	Hsa-mir-150	dbDEMC, miRCancer
	Hsa-mir-185	dbDEMC, miRCancer
	Hsa-mir-15b	dbDEMC
	Hsa-mir-98	dbDEMC, miRCancer
	Hsa-mir-192	dbDEMC
	Hsa-mir-542	PMID: 26272182
	Hsa-mir-196b	dbDEMC
	Hsa-mir-92b	dbDEMC
	Hsa-mir-186	dbDEMC
	Hsa-mir-30e	Unconfirmed
	Hsa-mir-372	dbDEMC
	Hsa-mir-130b	dbDEMC
	Hsa-mir-370	dbDEMC
	Hsa-mir-449a	Unconfirmed

C. miRCancer 2 Hsa-mir-663b Unconfirmed 3 Hsa-mir-138 dbDEMC 4 Hsa-mir-331 dbDEMC dbDEMC, miRCancer 5 Hsa-mir-185 Hsa-mir-372 dbDEMC 6 Hsa-mir-378a Unconfirmed 7 8 Hsa-mir-1224 Unconfirmed Hsa-mir-130a dbDEMC, miRCancer 9 10 Hsa-mir-98 dbDEMC, miRCancer 11 Hsa-mir-532 dbDEMC dbDEMC 12 Hsa-mir-370 Hsa-mir-542 Unconfirmed 13 14 Hsa-mir-498 dbDEMC 15 Hsa-mir-371a Unconfirmed 16 Hsa-mir-142 miRCancer 17 Hsa-mir-130h dbDEMC Hsa-mir-150 dbDEMC, miRCancer 18 19 Hsa-mir-449a Unconfirmed dbDEMC 20Hsa-mir-15b

Table 4 The top 20 potential colon neoplasms-related miRNAs predicted by NSIM and the confirmation of these associations. All of the top 20 colon neoplasms-related miRNAs have been confirmed based on the miRCancer and dbDEMC databases

Rank	miRNA	Evidences
1	Hsa-mir-20a	dbDEMC
2	Hsa-mir-18a	dbDEMC, miRCancer
3	Hsa-mir-19b	dbDEMC
4	Hsa-mir-21	dbDEMC, miRCancer
5	Hsa-mir-143	dbDEMC, miRCancer
6	Hsa-mir-19a	dbDEMC
7	Hsa-mir-155	dbDEMC, miRCancer
8	Hsa-mir-92a	PMID: 26463716
9	Hsa-mir-125b	PMID: 24774301
10	Hsa-mir-29b	PMID: 26466603
11	Hsa-mir-34a	dbDEMC, miRCancer
12	Hsa-mir-146a	dbDEMC
13	Hsa-mir-16	PMID: 22049153
14	Hsa-mir-106b	dbDEMC
15	Hsa-let-7a	miRCancer
16	Hsa-mir-181a	dbDEMC, miRCancer
17	Hsa-mir-31	dbDEMC, miRCancer
18	Hsa-mir-15a	dbDEMC
19	Hsa-mir-150	PMID: 24705249
20	Hsa-mir-221	dbDEMC

known verified miRNA-disease associations related to predictive diseases. This operation ensured that we only used known miRNA-disease association and similarity information of other diseases to predict candidate miRNAs related to the given disease while prioritizing these candidate miRNAs.

We take isolated disease *j* as an example, $VD_j = AS_j = null$ vector and $NSIM_M(i_j) = 0$. The predictor score between

miRNA *i* and disease *j* is calculated by NSIM_D(*i,j*). The disease similarity consists of disease semantic similarities (eqn (3) DD) and disease similarities of known miRNA-disease associations (eqn (6) DAS). When disease *j* is an isolated disease, DAS(*i,j*) = null vector; and DD calculated by disease MeSH DAG, do not depend on the associated miRNAs. What we call isolated disease refers to a disease without any known related miRNAs, and the associations between the disease and other diseases exists. So we use DD(*i,j*) as SD(i,j) to calculate NSIM_D(*i,j*). Therefore, our method can be applied to predict isolated disease-related miRNAs.

The average AUC of NSIM to predict isolated diseases is 0.8146. The predicted results of breast neoplasms are listed in Table 5.

Discussion

The recommendable performance of NSIM could be mainly attributed to the several factors. First, NSIM is a prediction method based on experimentally confirmed microRNA-disease associations. It integrates scores from disease space and microRNA space to construct a global network, which improves prediction accuracy. Second, the NSIM is an understandable method involving only one parameter, which is easy to adjust. Furthermore, new diseases (isolated diseases without any known related microRNA) are constantly being discovered. Thus, computational methods are used to predict isolated diseases. The NSIM performs well in predicting isolated diseases.

The current version of NSIM has limitations. Despite its good performance, the NSIM was constructed on basis of miRNAdisease associations. The number of associations affected the

View Article Online RSC Advances

prediction accuracy. The more the number of associations, the more accurate the prediction is. Hence, the performance of the NSIM could be improved by obtaining more miRNA-disease associations. Furthermore, this method only considers the semantic relation in calculating the disease similarity score. Information on gene-disease, miRNA-lncRNA, and miRNAtarget gene interactions could further improve the similarity measure between miRNAs and diseases.

Conclusions

Predicting potential microRNA-disease associations through computational methods can provide support for experimental studies on microRNAs. In this study, we proposed the NSIM to predict miRNA-disease associations by integrating miRNAs similarities, disease similarities, and known miRNA-disease associations. The NSIM obtained a high AUC of 0.9475 in LOOCV. Furthermore, case studies of prostate, breast, and colon neoplasms were implemented, and 19, 17, and 20 miR-NAs in the top 20 prediction list were confirmed, respectively. These results demonstrate that NSIM can effectively identify potential disease-related miRNAs. NSIM also performs well in predicting isolated diseases. The results demonstrated that the performance of the NSIM is superior to that of other existing prediction methods. The NSIM could be an effective biological tool that can be extended to research on drug-disease and environmental factor-disease associations.

References

- 1 A. M. Krichevsky, K. S. King, C. P. Donahue, K. Khrapko and K. S. Kosik, *RNA*, 2003, **9**, 1274–1281.
- 2 Q. H. Cui, Z. B. Yu, E. O. Purisima and E. Wang, *Mol. Syst. Biol.*, 2006, 2.
- 3 T. Du and P. D. Zamore, Cell Res., 2007, 17, 661-663.
- 4 E. Berezikov, E. Cuppen and R. H. Plasterk, *Nat. Genet.*, 2006, (38), S2–S7.
- 5 D. P. Bartel, Cell, 2009, 136.
- 6 E. A. Miska, Curr. Opin. Genet. Dev., 2005, 15, 563-568.
- 7 J. Kim, K. Inoue, J. Ishii, W. B. Vanti, S. V. Voronov, E. Murchison, G. Hannon and A. Abeliovich, *Science*, 2007, 317.
- 8 A. Esquela-Kerscher and F. J. Slack, *Nat. Rev. Cancer*, 2006, **6**, 259–269.
- 9 J. P. Cogswell, J. Ward, I. A. Taylor, M. Waters, Y. Shi, B. Cannon, K. Kelnar, J. Kemppainen, D. Brown and C. Chen, *J. Alzheimer's Dis.*, 2008, 14.
- 10 P. K. Mishra, N. Tyagi, M. Kumar and S. C. Tyagi, J. Cell. Mol. Med., 2009, 13, 778–789.
- J. Ribas, X. H. Ni, M. Haffner, E. A. Wentzel, A. H. Salmasi, W. H. Chowdhury, T. A. Kudrolli, S. Yegnasubramanian, J. Luo, R. Rodriguez, J. T. Mendell and S. E. Lupold, *Cancer Res.*, 2009, 69, 7165–7169.
- 12 M. Han, Y. Wang, M. Liu, X. Bi, J. Bao, N. Zeng, Z. Zhu, Z. Mo, C. Wu and X. Chen, *Cancer Sci.*, 2012, **103**, 1058–1064.
- 13 M. Lu, Q. Zhang, M. Deng, J. Miao, Y. Guo, W. Gao and Q. Cui, *PLoS One*, 2008, 3.

- 14 Q. Jiang, Y. Wang, Y. Hao, L. Juan, M. Teng, X. Zhang, M. Li, G. Wang and Y. Liu, *Nucleic Acids Res.*, 2009, 37.
- 15 Z. Yang, F. Ren, C. N. Liu, S. M. He, G. Sun, Q. A. Gao, L. Yao,Y. D. Zhang, R. Y. Miao, Y. Cao, Y. Zhao, Y. Zhong andH. T. Zhao, *BMC genomics*, 2010, 11.
- 16 B. Xie, Q. Ding, H. Han and D. Wu, *Bioinformatics*, 2013, **29**, 638–644.
- 17 X. Zeng, X. Zhang and Q. Zou, *Briefings Bioinf.*, 2016, **17**, 193–203.
- 18 Q. H. Jiang, Y. Y. Hao, G. H. Wang, L. R. Juan, T. J. Zhang, M. X. Teng, Y. L. Liu and Y. D. Wang, *BMC Syst. Biol.*, 2010, 4.
- 19 D. Wang, J. A. Wang, M. Lu, F. Song and Q. H. Cui, *Bioinformatics*, 2010, 26, 1644–1650.
- 20 X. Chen, M. X. Liu and G. Y. Yan, Mol. BioSyst., 2012, 8.
- 21 H. Shi, J. Xu, G. Zhang, L. Xu, C. Li, L. Wang, Z. Zhao, W. Jiang, Z. Guo and X. Li, *BMC Syst. Biol.*, 2013, 7, 1–12.
- 22 P. Xuan, K. Han, M. Guo, Y. Guo, J. Li, J. Ding, Y. Liu, Q. Dai, J. Li, Z. Teng and Y. Huang, *PLoS One*, 2013, **8**, e70204.
- 23 H. Shi, G. Zhang, M. Zhou, L. Cheng, H. Yang, J. Wang, J. Sun and Z. Wang, *PLoS One*, 2016, **11**, e0148521.
- 24 X. Chen, C. C. Yan, X. Zhang, Z. H. You, L. X. Deng, Y. Liu,Y. D. Zhang and Q. H. Dai, *Sci. Rep.*, 2016, 6.
- 25 J. Luo, P. Ding, C. Liang, B. Cao and X. Chen, *IEEE/ACM Trans. Comput. Biol. Bioinf.*, 2016, DOI: 10.1109/ TCBB.2016.2599866.
- 26 Q. Zou, J. Li, Q. Hong, Z. Lin, Y. Wu, H. Shi and Y. Ju, *BioMed Res. Int.*, 2015, 2015, 810514.
- 27 Q. Jiang, G. Wang, S. Jin, Y. Li and Y. Wang, *Int. J. Data Min. Bioinform.*, 2013, **8**, 282–293.
- 28 X. Chen and G. Y. Yan, Sci. Rep., 2014, 4, 5501.
- 29 Q. Jiang, G. Wang and Y. Wang, An approach for prioritizing disease-related microRNAs based on genomic data integration, Biomedical Engineering and Informatics (BMEI), 2010 3rd International Conference On, IEEE, 2010, vol. 6, pp. 2270– 2274.
- 30 J. Xu, C. X. Li, J. Y. Lv, Y. S. Li, Y. Xiao, T. T. Shao, X. Huo, X. Li, Y. Zou, Q. L. Han, X. Li, L. H. Wang and H. Ren, *Mol. Cancer Ther.*, 2011, **10**, 1857–1866.
- 31 S. Bandyopadhyay, R. Mitra, U. Maulik and M. Q. Zhang, *Silence*, 2010, 1, 6.
- 32 A. Schlicker, T. Lengauer and M. Albrecht, *Bioinformatics*, 2010, **26**, i561–i567.
- 33 J. Jiang, E. J. Lee, Y. Gusev and T. D. Schmittgen, *Nucleic Acids Res.*, 2005, 33.
- 34 K. Musilova and M. Mraz, Leukemia, 2015, 29, 1004-1017.
- 35 S. McGuire, Adv. Nutr., 2016, 7, 418-419.
- 36 J. Weidhaas, Lancet Oncol., 2010, 11.
- 37 P. D. Baade, D. R. Youlden and L. J. Krnjacki, *Mol. Nutr. Food Res.*, 2009, **53**, 171–184.
- 38 M. Alshalalfa, G. D. Bader, A. Goldenberg, Q. Morris and R. Alhajj, *BMC Syst. Biol.*, 2012, **6**, 112.
- 39 M. Jin, T. Zhang, C. Liu, M. A. Badeaux, B. Liu, R. Liu, C. Jeter, X. Chen, A. V. Vlassov and D. G. Tang, *Cancer Res.*, 2014, 74, 4183–4195.

- 40 E. Guzel, O. F. Karatas, A. Semercioz, S. Ekici, S. Aykan, S. Yentur, C. J. Creighton, M. Ittmann and M. Ozen, *Int. J. Cancer*, 2015, **136**, 875–879.
- 41 A. Y. Gong, A. N. Eischeid, J. Xiao, J. Zhao, D. Chen,Z. Y. Wang, C. Y. Young and X. M. Chen, *BMC Cancer*, 2012, 12, 492.
- 42 R. Ottman, J. Levy, W. E. Grizzle and R. Chakrabarti, *OncoTargets Ther.*, 2016, 7, 73739–73753.
- 43 H. L. Wu and Y. Y. Mo, *Expert Opin. Ther. Targets*, 2009, **13**, 1439–1448.
- 44 T. He, F. Qi, L. Jia, S. Wang, C. Wang, N. Song, Y. Fu, L. Li and Y. Luo, *Cancer Lett.*, 2015, **368**, 115–125.
- 45 A. Drusco, G. J. Nuovo, N. Zanesi, G. Di Leva, F. Pichiorri,
 S. Volinia, C. Fernandez, A. Antenucci, S. Costinean,
 A. Bottoni, I. A. Rosito, C. G. Liu, A. Burch, M. Acunzo,
 Y. Pekarsky, H. Alder, A. Ciardi and C. M. Croce, *Plos One*, 2014, 9.
- 46 R. Siegel, C. DeSantis and A. Jemal, *Ca-Cancer J. Clin.*, 2014, 64, 104–117.
- 47 J. J. Ye and J. Cao, World J. Gastroenterol., 2014, 20, 4288– 4299.